FDA requests Alcon run more tests on Retaane

NEW YORK The Food and Drug Administration has requested that Alcon conduct additional clinical studies on its approved drug Retaane, which is designed for the treatment of wet age-related macular degeneration, an eye disease.

The company does not immediately plan on conducting the new trials due to the difficulty of recruiting patients. It will continue, however, to support an ongoing trial of Retaane in relation to reducing the risk of age-related macular degeneration to progress from the dry to wet form.

The drug is available in countries outside the U.S.